Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jul;7(7):401-14.
doi: 10.1038/nrclinonc.2010.64. Epub 2010 Jun 15.

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Filip Janku  1 , David J Stewart, Razelle Kurzrock
Affiliations
Review

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Filip Janku et al. Nat Rev Clin Oncol. 2010 Jul.

Erratum in

  • Nat Rev Clin Oncol. 2011 Jul;8(7):384

Abstract

Treatment outcomes in advanced or metastatic non-small-cell lung cancer (NSCLC) remain unsatisfactory, with low long-term survival rates. Palliative chemotherapy offers a median survival not exceeding 1 year. To date, various combinations of cytotoxic drugs have not improved treatment results beyond what has been observed with platinum doublets. By contrast, molecular targeted drugs may block important pathways that drive cancer progression and achieve long-term disease control. Conflicting results have demonstrated marginal benefit with EGFR inhibitors, anti-EGFR monoclonal antibodies and antiangiogenic strategies in unselected populations of patients with advanced NSCLC. However, patients with an EGFR mutation are likely to respond to agents that target this gene. Novel targeted therapies that interfere with insulin-like growth factor 1 receptor, or the EML4-ALK fusion protein have shown promising activity. Aberrations in other key signaling pathways and molecules, such as RAS/RAF/MEK, PI3K/AKT/mTOR, or MET kinase, have been identified as crucial targets, especially in resistant patients. Novel drugs aimed at these abnormalities are already in the clinic. This Review outlines the current state-of-the-art research for targeted therapy in NSCLC.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Clin Oncol. 2010 Feb 20;28(6):918-27 - PubMed
    1. Mol Cancer Ther. 2007 Apr;6(4):1175-9 - PubMed
    1. Nat Med. 2008 Dec;14(12):1351-6 - PubMed
    1. N Engl J Med. 2009 Sep 3;361(10):947-57 - PubMed
    1. J Clin Oncol. 2010 Feb 20;28(6):911-7 - PubMed

MeSH terms